The purpose of the new company Neostell is to produce Neovacs' Kinoid immunotherapy product candidates including IFNα-Kinoid, in clinical development for the treatment of systemic lupus erythematosus (lupus).
“The alarming rise of Zika, and the sharp increase in neurological disorders seen in affected areas, intensifies the need to develop a safe and effective vaccine capable of
Vernalis and Servier have been working in partnership using Vernalis' proprietary fragment and structure-based drug discovery platform on a number of oncology targets, including Bcl-2 and Mcl-1. This
The LIBERTY study will evaluate the effects of ubenimex added to current standard of care in patients with pulmonary arterial hypertension (PAH). Despite multiple approved vasodilator therapies, PAH
This approval will initiate the first store brand launch of an equivalent product to Zegerid OTC capsules. This product will be packaged and marketed as a store brand or
The high demand for site-specific labeling technologies and potential for deal-making in the field of antibody-drug conjugates (ADC) that has emerged during APC's recent business development activities, particularly
The Company intends to use the net proceeds from this capital increase as follows: • To initiate and progress the Phase 3 Imeglimin program in Japan
The ANDA is owned jointly by Fera and Oakwood. Indicated for myxedema coma, the companies believe the product will enjoy 180-day generic drug exclusivity upon launch. Frank DellaFera,
Additionally, the company is providing an update on the ongoing irritable bowel syndrome with constipation (IBS-C) program. “We are pleased with the progress and ongoing dialogue with the
The FDA issues CRLs to indicate that the Agency considers the review cycle for an application is complete and whether the application is ready for approval in its
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.